These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 22374407)

  • 21. Oral hypoglycaemic agents. When, how and why.
    Harris P; Colagiuri S
    Aust Fam Physician; 1997 Apr; 26(4):391-6. PubMed ID: 9115112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Delayed sulfonylurea resistance in non-insulin-dependent diabetes mellitus].
    Farkas K; Jermendy G; Somogyi A
    Orv Hetil; 1997 Nov; 138(48):3031-5. PubMed ID: 9441264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exorcising the specter of nighttime hypoglycemia.
    Scheiner G
    Diabetes Self Manag; 2012; 29(1):16, 18-20. PubMed ID: 22482132
    [No Abstract]   [Full Text] [Related]  

  • 24. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients: response to Rosenstock et al.
    Hamid Z; Simmons DL
    Diabetes Care; 2006 Oct; 29(10):2331; author reply 2332. PubMed ID: 17003324
    [No Abstract]   [Full Text] [Related]  

  • 25. Roundtable. Blueprint for conversion of patients on metformin and sulfonylurea to Glucovance.
    Roselli A; Hayes JD; Seidner R; Marchione V; Snyder CM; Mayes K; Stiernberg CM; Milgram L
    Manag Care; 2001 Feb; 10(2 Suppl):17-21. PubMed ID: 11729404
    [No Abstract]   [Full Text] [Related]  

  • 26. [Measures to meet the side effects of sulfonylurea (SU) in the treatment of type 2 diabetes].
    Furukawa H; Ishida H
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():357-61. PubMed ID: 12387018
    [No Abstract]   [Full Text] [Related]  

  • 27. Combination therapy with liraglutide and sulfonylurea for a type 2 diabetic patient with high titer of anti-insulin antibodies produced by insulin therapy.
    Yoshida M; Asai M; Miyata M; Ogawa K; Maeda H; Oiso Y
    Diabetes Res Clin Pract; 2012 Jun; 96(3):e55-6. PubMed ID: 22257418
    [No Abstract]   [Full Text] [Related]  

  • 28. Rosiglitazone/glimepiride (Avandaryl) for diabetes.
    Med Lett Drugs Ther; 2006 Mar; 48(1230):22-4. PubMed ID: 16538189
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials.
    Johnson JL; Wolf SL; Kabadi UM
    Arch Intern Med; 1996 Feb; 156(3):259-64. PubMed ID: 8572835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Metformin--its regimen and effects].
    Shiba T
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():382-8. PubMed ID: 12387022
    [No Abstract]   [Full Text] [Related]  

  • 31. Effectiveness and side effects of thiazolidinediones for type 2 diabetes.
    Morton AP; McIntyre HD
    Med J Aust; 2005 May; 182(9):492-3. PubMed ID: 15865597
    [No Abstract]   [Full Text] [Related]  

  • 32. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy.
    McAlister FA; Eurich DT; Majumdar SR; Johnson JA
    Eur J Heart Fail; 2008 Jul; 10(7):703-8. PubMed ID: 18571471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical characteristics of withdrawal from insulin therapy in NIDDM].
    Kanda T; Imano E; Iida M; Kawamori R
    Nihon Rinsho; 1997 Nov; 55 Suppl():727-32. PubMed ID: 9434555
    [No Abstract]   [Full Text] [Related]  

  • 34. Rosiglitazone + glimepiride: new drug. Another combination product to avoid.
    Prescrire Int; 2007 Aug; 16(90):144. PubMed ID: 17726795
    [No Abstract]   [Full Text] [Related]  

  • 35. [Minor differences in outcome comparing early vs. later initiation of medicamentous blood glucose control in type 2 diabetic patients].
    Ritzman P
    Praxis (Bern 1994); 1999 Aug; 88(31-32):1289-90. PubMed ID: 10479970
    [No Abstract]   [Full Text] [Related]  

  • 36. [Warning signals insulin resistance. Insulin resistance causes not only diabetes].
    MMW Fortschr Med; 2004 Jul; 146(29-30):49. PubMed ID: 15540564
    [No Abstract]   [Full Text] [Related]  

  • 37. [New pharmacological treatment methods of type 2 diabetes].
    Madsbad S; Hermansen K
    Ugeskr Laeger; 2012 Sep; 174(37):2143-6. PubMed ID: 22971293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progressing From Metformin to Sulfonylureas or Meglitinides.
    Grant JS; Graven LJ
    Workplace Health Saf; 2016 Sep; 64(9):433-9. PubMed ID: 27621259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Type 2 diabetes: which drug as add-on to metformin?
    Madsbad S
    Lancet; 2012 Jun; 379(9833):2222-3. PubMed ID: 22683136
    [No Abstract]   [Full Text] [Related]  

  • 40. Successful treatment of markedly symptomatic patients with type II diabetes mellitus using high doses of sulfonylurea agents.
    Davidson MB
    West J Med; 1992 Aug; 157(2):199-200. PubMed ID: 1441492
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.